All Articles
Dr Tycel Phillips discusses the rationale of an “active surveillance” paradigm following initial diagnosis of follicular lymphoma (FL), as well as how to best select patients in whom this approach could be optimally applied, especially considering FL is currently still an incurable disease. Read More ›
Dr David M. O’Malley, Professor, Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and Director of the Division of Gynecologic Oncology at the OSUCCC – James, discusses his perspectives on the current treatment landscape and optimal clinical management of patients with advanced ovarian cancer who are given PARP-is as maintenance therapy in the first-line setting. Read More ›
Dr Andrew Zelenetz explains the basis for the currently nearly universal use of the end point of “progression of disease in 24 months” (POD24) as a metric in patients with relapsed follicular lymphoma (FL) to identify a high-risk subpopulation. He also discusses how POD24 impacts the choice of therapy and assessing the impact of the next line of therapy. Dr Tycel Phillips emphasized the importance of repeat biopsy in patients with relapsed or refractory FL, to exclude the presence of histologic transformation of FL into a high-grade diffuse large B-cell lymphoma, which necessitates expeditious detection, staging, and aggressive therapy. Read More ›
In the phase 3 DETERMINATION trial—in which patients with newly diagnosed multiple myeloma were randomly assigned to a standard triplet regimen with and without autologous stem-cell transplantation (ASCT), with all receiving lenalidomide (Revlimid) maintenance therapy until disease progression—patients with ASCT had significantly longer progression-free survival (PFS) versus those who did not, but no difference in overall survival (OS) was observed between the 2 treatment arms. Read More ›
Based on their anatomic site of origin, cholangiocarcinomas (CCAs) are classified as intrahepatic (iCCA), perihilar (pCCA), or distal (dCCA). Read More ›
It is common for employees in the healthcare industry to begin their careers in entry-level positions and then move on to other positions as they acquire on-the-job training and experience. However, additional education and training is often necessary to ensure that their skills match an organization’s goals and requirements. These needs can be addressed through skills gap assessments and training. Read More ›
Dual immune checkpoint inhibition with the anti–PD-L1 antibody durvalumab (Imfinzi) and the investigational anti–CTLA-4 antibody tremelimumab combined with platinum-based chemotherapy showed promising clinical activity and a favorable safety profile in the neoadjuvant setting for patients with advanced ovarian cancer, according to results of a single-arm phase 2 study presented during the 2022 American Association for Cancer Research Annual Meeting. Read More ›
The addition of a novel bispecific antibody to preactivated and expanded natural killer (NK) cells may represent an effective therapy for pretreated patients with relapsed or refractory CD30-positive lymphoma, according to preliminary findings from a phase 1/2 clinical trial presented during the 2022 American Association for Cancer Research Annual Meeting. Read More ›
By William King
The addition of pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) resulted in significantly and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) in women with cervical cancer. Read More ›